KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Income (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Net Income data on record, last reported at -$31.9 million in Q4 2025.

  • For Q4 2025, Net Income fell 86.81% year-over-year to -$31.9 million; the TTM value through Dec 2025 reached -$83.8 million, down 89.83%, while the annual FY2025 figure was -$83.8 million, 89.83% down from the prior year.
  • Net Income reached -$31.9 million in Q4 2025 per AQST's latest filing, down from -$15.4 million in the prior quarter.
  • Across five years, Net Income topped out at $8.1 million in Q1 2023 and bottomed at -$31.9 million in Q4 2025.
  • Average Net Income over 5 years is -$13.0 million, with a median of -$13.0 million recorded in 2022.
  • Peak YoY movement for Net Income: surged 161.03% in 2023, then crashed 465.55% in 2024.
  • A 5-year view of Net Income shows it stood at -$28.9 million in 2021, then skyrocketed by 57.33% to -$12.4 million in 2022, then skyrocketed by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then crashed by 86.81% to -$31.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$31.9 million in Q4 2025, -$15.4 million in Q3 2025, and -$13.5 million in Q2 2025.